The value of information and optimal clinical trial design
暂无分享,去创建一个
[1] A R Willan,et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] D Polsky,et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.
[3] A A Stinnett,et al. Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.
[4] Bernie J. O'Brien,et al. In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.
[5] Hamid. Pezeshk,et al. How large should a clinical trial be , 2000 .
[6] K Claxton,et al. An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.
[7] J Halpern,et al. Designing a cost-effective clinical trial. , 1995, Statistics in Medicine.
[8] The assessment of the economic return from controlled clinical trials , 2003, The European Journal of Health Economics.
[9] J. Lachin. Introduction to sample size determination and power analysis for clinical trials. , 1981, Controlled clinical trials.
[10] C. J. Adcock,et al. The choice of sample size. Commentaries. Author's reply , 1997 .
[11] A R Willan,et al. Argon green vs. krypton red laser photocoagulation for extrafoveal choroidal neovascularization secondary to age-related macular degeneration: 3-year results of a multicentre randomized trial. Canadian Ophthalmology Study Group. , 1996, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[12] P. Wakker,et al. Confidence intervals for cost/effectiveness ratios. , 1995, Health economics.
[13] Hamid Pezeshk,et al. Bayesian techniques for sample size determination in clinical trials: a short review , 2003, Statistical methods in medical research.
[14] A R Willan,et al. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. , 1996, Health economics.
[15] D. Heitjan,et al. Fieller's method and net health benefits. , 2000, Health economics.
[16] Stanley Lemeshow,et al. Adequacy of Sample Size in Health Studies , 1990 .
[17] J Hornberger,et al. The cost-benefit of a randomized trial to a health care organization. , 1998, Controlled clinical trials.
[18] M. J. R. Healy,et al. Economic Choice of the Amount of Experimentation , 1956 .
[19] S. Stearns,et al. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1996, Statistics in medicine.
[20] A R Willan,et al. Power function arguments in support of an alternative approach for analyzing management trials. , 1994, Controlled clinical trials.
[21] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R J Cook,et al. Using inverse-weighting in cost-effectiveness analysis with censored data , 2002, Statistical methods in medical research.
[23] N. Zethraeus,et al. Definition, interpretation and calculation of cost-effectiveness acceptability curves. , 2000, Health economics.
[24] John Gittins,et al. A Behavioral Bayes Method for Determining the Size of a Clinical Trial , 2000 .
[25] A O'Hagan,et al. Bayesian Assessment of Sample Size for Clinical Trials of Cost-Effectiveness , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[26] Howard Raiffa,et al. Applied Statistical Decision Theory. , 1961 .
[27] Hamid Pezeshk,et al. A Fully Bayesian Approach to Calculating Sample Sizes for Clinical Trials with Binary Responses , 2002 .
[28] A R Willan,et al. Analysis, sample size, and power for estimating incremental net health benefit from clinical trial data. , 2001, Controlled clinical trials.
[29] C E Phelps,et al. On the (Near) Equivalence of Cost-Effectiveness and Cost-Benefit Analyses , 1991, International Journal of Technology Assessment in Health Care.
[30] H. Raiffa,et al. Applied Statistical Decision Theory. , 1961 .
[31] Andrew R Willan,et al. Incremental net benefit in randomized clinical trials with quality‐adjusted survival , 2003, Statistics in medicine.
[32] K M Thompson,et al. A dynamic programming approach to the efficient design of clinical trials. , 2001, Journal of health economics.
[33] Darren McKay,et al. External cephalic version beginning at 34 weeks' gestation versus 37 weeks' gestation: a randomized multicenter trial. , 2003, American journal of obstetrics and gynecology.
[34] M Johannesson,et al. A Note on Confidence Intervals in Cost-Effectiveness Analysis , 1998, International Journal of Technology Assessment in Health Care.
[35] R. Baltussen,et al. The interpretation of results of economic evaluation: explicating the value of health. , 1997, Health economics.
[36] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[37] D Y Lin,et al. Incremental net benefit in randomized clinical trials , 2001, Statistics in medicine.
[38] A H Briggs,et al. A Bayesian approach to stochastic cost-effectiveness analysis. , 1999, Health economics.
[39] John Gittins,et al. Quantitative Methods in the Planning of Pharmaceutical Research , 1996 .
[40] Andrew R Willan,et al. Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial , 2000, The Lancet.
[41] A Briggs,et al. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.
[42] D. Lindley. The choice of sample size , 1997 .
[43] B W Brown,et al. The sample size for a clinical trial: A Bayesian–decision theoretic approach , 2001, Statistics in medicine.
[44] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[45] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[46] Hamid Pezeshk,et al. Sample Size Determination in Clinical Trials , 1999 .